Quotient (NASDAQ: QTNT) and NanoString Technologies (NASDAQ:NSTG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Institutional & Insider Ownership
39.0% of Quotient shares are held by institutional investors. Comparatively, 90.1% of NanoString Technologies shares are held by institutional investors. 29.0% of Quotient shares are held by insiders. Comparatively, 24.4% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Quotient and NanoString Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Quotient and NanoString Technologies’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Quotient||$23.34 million||2.21||-$64.95 million||($2.92)||-1.23|
|NanoString Technologies||$101.82 million||3.09||-$35.93 million||($2.13)||-6.52|
NanoString Technologies has higher revenue and earnings than Quotient. NanoString Technologies is trading at a lower price-to-earnings ratio than Quotient, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Quotient has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Quotient and NanoString Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Quotient presently has a consensus price target of $19.00, suggesting a potential upside of 430.73%. NanoString Technologies has a consensus price target of $20.00, suggesting a potential upside of 44.09%. Given Quotient’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Quotient is more favorable than NanoString Technologies.
NanoString Technologies beats Quotient on 7 of the 13 factors compared between the two stocks.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).
NanoString Technologies Company Profile
NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.
Receive News & Ratings for Quotient Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd and related companies with MarketBeat.com's FREE daily email newsletter.